Top Industry Leaders in the US Allergic Conjunctivitis Market
Alcon launches Pataday Once Daily Relief Extra Strength: This extended-release formulation of olopatadine hydrochloride offers 24-hour allergy symptom relief with a single daily dose.
Bausch & Lomb introduces Alaway Preservative Free Antihistamine Eye Drops: This first-of-its-kind over-the-counter option caters to patients with sensitive eyes who require preservative-free solutions.
Eyevance Pharmaceuticals receives FDA approval for ZERVIATE (cetirizine ophthalmic solution) 0.24%: This marks the first new prescription-only medication for allergic conjunctivitis approved in the US in over a decade.
Aciex Therapeutics partners with Alcon for commercialization of its novel ALK-specific immunotherapy for allergic conjunctivitis: This collaboration aims to bring a potentially transformative treatment option to patients faster.
Regen Therapeutics reports early promise for its RGN259 treatment in a Phase 2 study for allergic conjunctivitis: This gene therapy approach offers a potential long-term solution for managing allergy symptoms.
List of US Allergic Conjunctivitis Key companies in the market- Bausch & Lomb Incorporated
- Aldeyra Therapeutics
- Vanda Pharmaceuticals
- NoveomeBiotherapeutics
- Allakos, Inc.
- Regeneron Pharmaceuticals
- Marinomed Biotech AG
- Eleusis Holdings Ltd
- IACTA Pharmaceuticals
- W. Pharmaceutical
